scispace - formally typeset
E

Eric J. Topol

Researcher at Scripps Health

Publications -  1406
Citations -  162373

Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.

Papers
More filters
Journal ArticleDOI

Insights into the pathophysiology of atherosclerosis and prognosis of black Americans with acute coronary syndromes

TL;DR: As racially mediated biologic differences between black and white patients become better understood, targeted interventions to prevent coronary heart disease and treat acute coronary syndromes in black patients can be developed.
Journal ArticleDOI

Benefit of Early Sustained Reperfusion in Patients With Prior Myocardial Infarction (The GUSTO-I Trial)

TL;DR: Patients with healed myocardial infarction should be educated to ensure early hospital admission if they develop symptoms suggestive of acute infarctions, and upon hospital arrival should be promptly triaged to receive reperfusion therapy with accelerated alteplase.
Journal ArticleDOI

Digital medicine: empowering both patients and clinicians

TL;DR: The convergence of smartphone-enabled mobile computational and connectivity capabilities is only one aspect of digital medicine; it also encompasses genomics, information systems, wireless sensors, cloud computing, and machine learning that can all be incorporated into new systems of health management, built around realworld, patient-generated data.
Journal ArticleDOI

Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.

TL;DR: Bivalirudin with provisional GPIIb/IIIa inhibitor use in low-risk ACS patients (not receiving preprocedural GPIIB/ IIIa blockade) appears to provide similar protection against death and myocardial infarction as the combination of heparin and GPIIa-IIIa inhibitors, although the authors observed a higher rate of revascularization at 6 months.